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Abstract
Aims/hypothesis The association between increased (vis-
ceral) fat mass, insulin resistance and type 2 diabetes
mellitus is well known. Yet, it is unclear whether the mere
increase in intra-abdominal fat mass, or rather functional
alterations in fat tissue in obesity contribute to the
development of insulin resistance in obese patients. Here
we attempted to isolate the metabolic effect of increased fat
mass by fat tissue transplantation.
Methods Epididymal fat pads were removed from male
C57Bl6/J mice and transplanted intraperitoneally into male
littermates (recipients), increasing the combined peri-
gonadal fat mass by 50% ( p<0.005). At 4 and 8 weeks
post-transplantation, glucose and insulin tolerance tests were
performed, and insulin, NEFA and adipokines measured.
Results Circulating levels of NEFA, adiponectin and leptin
were not significantly different between transplanted and
sham-operated control mice, while results of the postpran-
dial insulin tolerance test were similar between the two
groups. In contrast, under fasting conditions, the mere
increase in intra-abdominal fat mass resulted in decreased
plasma glucose levels (6.9±0.4 vs 8.1±0.3 mmol/l,
p=0.03) and a ∼20% lower AUC in the glucose tolerance
test ( p=0.02) in transplanted mice. Homeostasis model
assessment of insulin resistance (HOMA-IR) was 4.1±0.4
in transplanted mice (vs 6.2±0.7 in sham-operated controls)
( p=0.02), suggesting improved insulin sensitivity. Linear
regression modelling revealed that while total body weight
positively correlated, as expected, with HOMA-IR
(β: 0.728, p=0.006), higher transplanted fat mass correlated
with lower HOMA-IR (β: −0.505, p=0.031).
Conclusions/interpretation Increasing intra-abdominal fat
mass by transplantation of fat from normal mice
improved, rather than impaired, fasting glucose tolerance
and insulin sensitivity, achieving an effect opposite to the
expected metabolic consequence of increased visceral fat
in obesity.
Keywords Fat transplantation . Glucose homeostasis .
Insulin resistance . Insulin sensitivity . Obesity .
Visceral adiposity
Abbreviations
HOMA-IR homeostasis model assessment of insulin
resistance
ipGTT intraperitoneal glucose tolerance test
ipITT intraperitoneal insulin tolerance test
Introduction
Obesity is caused by energy intake in excess of energy
expenditure, and is associated with an increased number
and/or size of white adipocytes, which store the excessive
energy in the form of triacylglycerol. The association
between increased fat mass, insulin resistance and type 2
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diabetes mellitus is well known. Yet, regional body fat
distribution may influence the occurrence of insulin
resistance associated with obesity. Increased accumulation
of visceral (intra-abdominal) fat seems to be particularly
associated with an increased risk of insulin resistance and
type 2 diabetes. Two major lines of observations suggest a
causative role for intra-abdominal fat in this association.
First, subjects with normal body weight, but with increased
visceral adiposity (e.g. elderly people or patients with
certain forms of lipodystrophy) are prone to develop insulin
resistance [1, 2]. Second, removal of intra-abdominal fat
improved insulin sensitivity [3, 4], whereas the removal of
subcutaneous fat tissue by liposuction in obese humans did
not improve insulin action [5]. Thus, the pattern of body fat
distribution, especially abdominal fat accumulation, deter-
mines insulin sensitivity.
One remaining question to define in this process is the
relative contributions of: (1) the mere increase in intra-
abdominal fat mass; and (2) the role of alterations in fat tissue
biology that accompany obesity. Increase in fat mass as such
has been suggested to increase the delivery of non-esterified
fatty acids through the portal circulation, resulting in
increased hepatic and muscular triacylglycerol accumulation
[6]. Similarly, altered adipose tissue biology can change
inter-organ cross-talk mechanisms through alterations in its
metabolic and/or endocrine function. For example, a recent
study demonstrated that the degree of macrophage infiltra-
tion into omental fat of obese patients correlated with
histopathological findings in liver biopsies [7].
To investigate the isolated role of a mere increase in
intra-abdominal fat in mice, we used intra-abdominal fat
transplantation to increase the intra-abdominal mass of
‘normal’ fat. We reasoned that if the mere increase in fat
mass is the predominant process occurring in obesity,
increasing intra-abdominal fat mass by surgical transplan-
tation of fat tissue from a normal, non-obese littermate
would induce metabolic consequences in the recipient
mice that resemble those occurring in obesity. If, on the
other hand, the predominating effect is obesity-induced
alterations in the endocrine function of fat tissue, the
addition of such fat mass would not impair metabolic
regulation.
Materials and methods
Animals Male C57BL6JOlaHsd mice were purchased from
Harlan Netherlands (Horst, the Netherlands). All mice were
housed in a pathogen-free environment on a 12-h light-dark
cycle, with free access to standard rodent diet (Provimi
Kliba, Kaiseraugst, Switzerland). All protocols conformed
to the Swiss animal protection laws and were approved by
the Cantonal Veterinary Office in Zurich, Switzerland.
Surgical procedure Transplantation procedure was per-
formed at 6 weeks of age. Mice were anaesthetised with
isoflurane (Abbott, Baar, Switzerland). Both epididymal fat
pads were removed from the donor mouse, rinsed with
0.9% saline and thereafter stitched to the visceral side of the
peritoneum of the recipient mouse using Vicryl 5.0
(Johnson-Johnson, Spreitenbach, Switzerland). Except for
a small piece of fat tissue fixed in 4% buffered formalin, the
entire two fat pads were weighed and then transplanted.
Sham-operated control mice received the same treatment,
but instead of the fat pad transplantation, an artificial suture
was performed with Vicryl. Subcutaneous injection of
buprenorphine every 12 h for 2 days was used for
analgesia. In order to prevent transplant rejection, donor
and recipient mice were littermates.
Glucose and insulin tolerance tests For fasting intraperito-
neal glucose tolerance test (ipGTT), either prolonged fasting
(overnight, i.e. 12 h food withdrawal) or 7 h food withdrawal
were used, as indicated. For intraperitoneal insulin tolerance
test (ipITT) in the post-absorptive state, mice were fed and
then fasted for 3 h. Either glucose (2 g/kg body weight) or
human normal insulin (0.75 U/kg body weight) were injected
intraperitoneally and blood was collected from the tail vein at
different time points, as indicated [8]. Plasma glucose was
measured using a glucose meter (Ascensia Contour; Bayer,
Zurich, Switzerland).
Determination of plasma insulin, adipokines and NEFA
levels Plasma was collected from the tail vein after 7 h of
fasting. Insulin was determined using an ELISA kit (Ultra
Sensitive Rat Insulin ELISA; Crystal Chem, Downers
Grove, IL, USA). NEFA levels were measured using the
ACS-ACOD-MEHA method (Wako Chemicals GmbH,
Neuss, Germany). Plasma leptin and adiponectin were
determined with commercially available mouse endocrine
and single plex adiponectin kits (MENDO-75K and
MADPK-71K-ADPN; Linco Research, distributed by
Labodia, Yens, Switzerland) that are capable of simulta-
neously measuring different adipokines in mouse serum or
plasma. The two kits are based on Luminex xMAP
technology (Linco Research, St Charles, MI, USA) and
use microsphere bead sets that are uniquely labelled with a
mixture of two fluorescent dyes. The captured antibodies
specific for each analyte are covalently coupled to
individual bead sets. At the time of the assay, a mixture
of beads is incubated overnight at 4°C with 10 μl of
standards or mouse plasma samples in a 96-well filter-
bottom plate. On the next day, the beads are washed, and
biotinylated detection antibody cocktail is added and
incubated for 30 min at room temperature, followed by
the addition of streptavidin-phycoerythrin and incubation
for another 30 min. After a final wash, the resuspended
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beads are read on a Luminex 100 reader (Bio-Rad
Laboratories, Hercules, CA, USA) and the concentration
of each analyte in the samples to be tested is determined on
the basis of individual standard curves.
Determination of homeostasis model assessment of insulin
resistance The homeostasis model assessment of insulin
resistance (HOMA-IR) was calculated using glucose and
insulin determinations obtained after 7 h of food withdraw-
al, using the following formula: fasting glucose (mmol/l)×
fasting insulin (mU/ml)/22.5 [9, 10].
Histology Epididymal fat tissues were fixed in 4% buffered
formalin and imbedded in paraffin. Sections were obtained
either at the time of transplantation or 8 weeks after
transplantation and stained with haematoxylin-eosin. For
each mouse at least four fields (representing a total of 350
to 550 adipocytes) were analysed. Images were analysed
using ImageJ software for quantification (National Insti-
tutes of Health, Bethesda, MD, USA).
Data analysis Statistical analyses of the obtained data were
performed using Student’s t test or ANOVA (Fisher’s
multiple comparisons test), as indicated. We performed
Pearson correlations between the continuous variables and
estimated the independent effect of fat transplantation by
further adjustment for total body weight using a linear
regression model (SPSS package software, version 14).
Results
Intraperitoneal fat transplantation increases intra-abdom-
inal fat mass without significantly altering circulating
adipokine levels To increase the intra-abdominal mass of
‘normal’ fat tissue, epididymal fat pads were removed from
a littermate donor and transplanted into the peritoneal
cavity of the recipient. At the timemicewere killed (10weeks
post-transplantation), transplanted fat pads were adherent to
the peritoneum and were vascularised (Fig. 1a,b). Sham
operations were performed in control littermates. Recipient
mice tolerated the surgical procedure and the fat transplan-
tation well, with no adverse events noted, and weight gain
during the ensuing 10 weeks comparable to that of sham-
operated littermate mice (Fig. 1c).
Recipient mice had a 50% increase in their combined
(endogenous + transplanted) intra-abdominal perigonadal
fat depot mass (p<0.005, Table 1). Fat tissue morphometry
was performed on histological sections stained with
haematoxylin-eosin (Fig. 2a). Adipocyte cell perimeter in
the transplanted and endogenous fat pads did not differ at
the time of transplantation (transplanted fat pad: 4,853±976
[arbitrary units], recipient endogenous fat pad: 4,056±785,
sham-operated fat pad: 4,170±798; p=0.72 ANOVA).
However, adipocytes of endogenous epididymal fat pads
in both sham-operated and recipient mice hypertrophied
from transplantation to time of killing (adipocyte perimeter
increase 1.64±0.28-fold, p<0.05 and 1.73±0.31-fold,
p<0.05, in sham-operated and recipient mice, respectively),
whereas adipocyte size of the transplanted fat pad did not
increase (0.91±0.14-fold, p=0.47)(Fig. 2b). The combined
intra-abdominal fat depot (endogenous + transplanted) did
not result in a significant difference in total body weight
between the recipient and control groups (Table 1). Con-
sistent with this observation, circulating levels of adipo-
nectin, leptin, resistin and NEFA (Table 1) in recipients
compared with sham-operated controls were not statistically
different (p=0.12, 0.15, 0.59 and 0.16, respectively). Thus,
Fig. 1 Intra-abdominal transplanted fat is viable and weight gain is
similar in sham-operated and recipient mice. a, b Six-week-old mice
received intraperitoneal transplantation of two epididymal fat pads
(approximately 175 mg) removed from a littermate donor, as detailed in
the Materials and methods. Sham-operated mice served as controls. At
10 weeks post-surgery, the abdominal cavity was opened, and trans-
planted (T) or endogenous (E) fat pads were visualised. a, sham; b,
recipient. c Weight gain in recipient (open circles) and sham-operated
littermate mice (closed squares). Results represent the mean±SEM of
eight or nine animals per group
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transplanted fat increased intra-abdominal mass of adipose
tissue while retaining adipocyte size of the transplanted fat,
but it did not alter total body weight or circulating levels of
secreted adipose tissue products.
Recipient mice with transplantation-mediated increase in
intra-abdominal fat mass exhibit improved glucose toler-
ance in the fasting state We first assessed whether intra-
abdominal fat transplantation altered insulin sensitivity in
the non-fasting state. For this, insulin sensitivity was
measured 4 weeks after transplantation, after overnight
feeding followed by 3 h of food withdrawal. Glucose
lowering during post-absorptive ipITT was identical be-
tween recipient and sham-operated littermate mice (Fig. 3).
To evaluate the effect of fat transplantation on glucose
homeostasis in the fasting state, ipGTTs were performed. At
4 weeks post-transplantation, overnight-fasted mice
exhibited improved glucose tolerance, as manifested by
lower plasma glucose levels at 15, 30, 45, 60, 90 and
120 min after glucose administration, resulting in a 20%
decrease in the AUC for glucose (recipient: 999±46, sham-
operated: 1267±66; p<0.001, Fig. 4a,b). To test whether
this effect was observable after a shorter fasting period,
mice were fasted for 7 h prior to ipGTT. Glucose levels
during ipGTT during these conditions were somewhat more
variable (as evidenced by larger SEMs), but overall,
recipient mice had lower glucose levels and lower mean
glucose AUCs than sham-operated controls (Fig. 4c,d).
Circulating insulin levels were also measured during ipGTT
(7 h of fasting) and tended to be lower in the transplanted
mice than in controls, particularly in the basal fasting state
(baseline: 79.8±8.2 vs 113.9±20.9 pmol/l, p=0.13; 15 min:
134.6±13.5 vs 150.2±7.6 pmol/l, p=0.41; 30 min: 126.7±
18.3 vs 139.8±19.3 pmol/l, p=0.62). These results suggest
that the post-challenge insulin secretory response was
maintained (and not exaggerated) in mice receiving intra-
peritoneal fat transplantation, while insulin sensitivity in the
fasting state was improved.
To further assess fasting insulin sensitivity, HOMA-IR
was calculated. Fasting glucose levels were significantly
(p=0.03) lower in recipient mice (Fig. 5a), while insulin
levels tended to be lower, although this difference did not
reach statistical significance (p=0.13, Fig. 5b). Neverthe-
less, HOMA-IR was found to be statistically (p=0.02)
lower in recipient mice than in sham-operated controls
(Fig. 5c), suggesting that an increase of intra-abdominal fat
mass by transplantation of normal fat in fact improved
fasting insulin sensitivity. To further verify this observation,
we assessed whether there was a ‘dose-effect’ between the
amount of transplanted fat and HOMA-IR. Consistent with
the expected relationship between body mass and insulin
sensitivity, total body weight at the time mice were killed
positively correlated with HOMA-IR (r=0.672, p=0.024)
Table 1 Total body weight, perigonadal fat pad weight and
circulating plasma levels of adipokines and NEFA
Sham Recipient p value
Body weight (g) 28.0±0.7 27.4±0.9 0.42
Fat depots
Perigonadal depots, total (mg) 365±22 508±23 <0.005
Endogenous fat pad (mg) 365±22 320±18 0.32
Transplanted fat pad (mg) 188±9
Circulating adipokines
Adiponectin (μg/ml) 13.2±1.0 11.1±0.8 0.12
Leptin (pg/ml) 1,330±180 1,075±71 0.15
Resistin (pg/ml) 2,214±407 1,912±421 0.59
NEFA (mmol/l) 1.14±0.08 1.01±0.04 0.16
Fig. 2 Adipocyte size of transplanted fat pads remains stable over time. a
Representative, haematoxylin- and eosin-stained histological sections of
endogenous or transplanted fat pads from recipient or sham-operated
mice at the time of transplantation or after killing (10 weeks later).
Adipocyte cell perimeter was measured using ImageJ. b Up to 470 cells
for each fat pad were analysed. The mean ± SEM of four different mice is
depicted here. All values are expressed relative to the adipocyte cell
perimeter of transplanted epididymal fat pad at the time of transplanta-
tion. Black bar, endogenous fat pad of sham-operated mice; white bar,
transplanted fat pad of recipient mice; grey bar, endogenous fat pad of
recipient mice
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by simple correlation analysis, whereas correlation between
the transplanted fat weight and HOMA-IR tended to be
negative (r=−0.42, p=0.19) (Fig. 5d). Therefore, to
evaluate the effect of fat transplantation independently of
total body weight, we assessed the association between the
transplanted fat weight and HOMA-IR, while adjusting for
total body weight at time of death. Using a linear regression
model, we found that the beta coefficient between the
transplanted fat weight and HOMA-IR was −0.505, p=
0.031, while the β coefficient in the same model for total
body weight was 0.728, p=0.006. This suggests that,
independently of the positive relationship between
HOMA-IR and total body weight, increasing the amount
of transplanted fat predicts increased fasting insulin
sensitivity.
Discussion
It is unclear whether increased intra-abdominal fat mass as
such or altered fat tissue biology contributes to the
metabolic derangement associated with obesity. The first
notion is supported by findings that intra-abdominal fat
mass reduction improves insulin sensitivity in rats [4],
whereas implantation of cultured adipocytes into the
peritoneal cavity of mice induces insulin resistance [11].
Here we used intra-abdominal fat tissue transplantation to
increase fat mass. Surprisingly, lean recipients of epididy-
mal fat transplant from lean littermates exhibited improved
fasting glucose tolerance and increased insulin sensitivity.
Thus, increasing intra-abdominal fat mass by transplanta-
tion of normal adipose tissue did not mimic the effects of
increased fat mass in obesity.
In this model, fat mass of transplanted fat tissue was
inversely correlated with HOMA-IR, independently of the
expected positive association between total body weight
and HOMA-IR. Histological examination of the trans-
planted adipose tissue revealed that after 10 weeks of
observation (transplantation to scarification) adipocyte cell
size increased significantly in endogenous fat pads, whereas
it remained unchanged in the transplanted fat pads
Fig. 5 The effect of fat transplantation on fasting glucose, insulin and
HOMA-IR. Fasting plasma glucose (a) and insulin (b) were measured
in recipient and sham-operated mice after 7 h of food withdrawal, and
HOMA-IR (c) was calculated as detailed in the Methods section.
Results represent the mean±SEM of 11 to 12 different animals per
group. d Pearson correlation between HOMA-IR and total body
weight (stars, continuous line) (r=0.672, p=0.024) or transplanted fat
pad weight (open circles, dotted line) (r=−0.42, p=0.19) was
performed. * p<0.05; # p=0.13
Fig. 3 Intra-abdominal transplantation of fat tissue does not alter
post-absorptive insulin tolerance. Intraperitoneal ITT (0.75 U/kg body
weight) was performed 4 weeks after surgery in recipient (open
circles) and sham-operated mice (filled squares) that had fasted for
3 h. Blood was collected from the tail vein at the indicated time points.
Results are the mean±SEM of nine or ten different animals in each
group
Fig. 4 Lean mice with transplantation-mediated increase in intra-
abdominal fat mass exhibit improved fasting glucose tolerance.
Intraperitoneal GTT (2 g glucose/kg body weight) was performed
4 weeks after surgical procedure in recipient (open circles) and sham-
operated mice (filled squares) that had fasted overnight (a, b) or for
only 7 h (c, d). Results are expressed as mean plasma glucose
concentration or AUC±SEM from 15 (sham) or 16 (recipient) animals
(a, b) or from six (sham) or seven (recipient) animals (c, d). *p<0.05,
**p<0.01, ***p<0.001 (Student’s t test)
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(Fig. 2b). Insulin action was previously shown to be
dependent on fat cell size: large adipocytes correlate well
with insulin resistance [12–14] and show decreased insulin-
stimulated glucose uptake [15]. Interestingly, the trans-
planted fat depot exhibited features reminiscent of those
induced in adipose tissue by thiazolidinediones. These
drugs were shown to increase cellularity in adipose tissue
by promoting fat cell differentiation and inducing apoptosis
of large adipocytes, resulting in smaller, more insulin-
sensitive adipocytes that secrete higher levels of adiponec-
tin [16, 17]. It is thus possible that the insulin-sensitising
effects of the transplant are secondary to similar alterations
in the transplanted adipose tissue. We therefore assessed
whether alterations in circulating levels of secretory
products of fat tissue mediated the improved glucose
tolerance and increased insulin sensitivity in mice receiving
fat transplantation. However, we did not observe any
significant increases in the circulating levels of potential
insulin-sensitising adipokines like leptin or adiponectin [18]
or any significant decreases in factors associated with
reduced insulin sensitivity (resistin and NEFA, Table 1).
Although potentially informative, such analysis is
limited in at least two major aspects. First, we measured
total adiponectin levels, but recent studies suggest that the
circulating high-molecular-mass complex of adiponectin
correlates better with insulin sensitivity than total serum
adiponectin levels [19, 20]. Second, with regard to the
unaltered circulating levels of adipokines and NEFA
observed by us, it should be noted that venous drainage
of intra-abdominal fat is to the portal system. It therefore
remains possible that intra-portal levels of secreted products
were affected, thereby predominantly influencing liver
glucose homeostasis. Such a scenario, in which the greatest
effect of intra-abdominal fat tissue transplantation is seen in
the liver, is also supported by the fact that the insulin-
sensitising effects of intra-abdominal fat transplantation
was largely observed in the fasting state, conditions in
which glycaemia is largely controlled by hepatic glucose
production and insulin sensitivity.
In conclusion, our findings suggest that in addition to
increased fat mass, altered adipose tissue function is
required to reproduce obesity-related metabolic changes
such as insulin resistance. These changes may include
impaired metabolic function of adipocytes, changes in
cellular composition of adipose tissue (e.g. macrophage
infiltration) [21] and/or alterations in the secretory function
of adipose tissue (inflammatory cytokines, adipokines,
NEFA). The second possible conclusion is that augmenta-
tion of normally functioning adipose tissue appears to result
in a new metabolic steady state with increased insulin
sensitivity. Such compensation and adaptation mechanisms
may be unable to counterbalance larger degrees of fat tissue
expansion. Yet, the results suggest that multiple factors in
the cross-talk mechanisms between different insulin-sensi-
tive tissues need to be affected in order to impair glucose
homeostasis in obesity. The notion that adipose tissue
function (rather than mass) and its inter-organ cross-talk are
key determinants of obesity-induced metabolic derange-
ment further defines this disorder as an endocrinopathy, and
adipose tissue as an endocrine organ.
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